Cost-effectiveness thresholds: methods for setting and examples from around the world

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 18, Issue 3, 2018, Pages 277-288

  Santos, André Soares ^a   Guerra Junior, Augusto Afonso ^a   Godman, Brian ^b,c   Morton, Alec ^d   Ruas, Cristina Mariano ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

Cost benefit analysis; cost effectiveness analysis; economics, medical; economics, pharmaceutical; expert testimony; review; technology assessment, biomedical

Indexed keywords

BIOMEDICAL TECHNOLOGY ASSESSMENT; COST EFFECTIVENESS ANALYSIS; ECONOMICS; EXPERT WITNESS; HUMAN; MEDLINE; REVIEW; SCIENCEDIRECT; SYSTEMATIC REVIEW; WELFARE; BRAZIL; COST BENEFIT ANALYSIS; ECONOMIC MODEL; HEALTH CARE DELIVERY; PATIENT ATTITUDE; PROCEDURES;

BRAZIL; COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; HUMANS; MODELS, ECONOMIC; PATIENT ACCEPTANCE OF HEALTH CARE; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 85048516602     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1080/14737167.2018.1443810     Document Type: Review

References (123)

1. World Health Organization. Using health technology assessment for universal health coverage and reimbursement systems. Geneva: World Health Organization; 2016. Available from: http://www.who.int/health-technology-assessment/HTA_November_meeting_report_Final.pdf?ua=1.
2. Schwarzer R, Rochau U, Saverno K, et al. Systematic overview of cost-effectiveness thresholds in ten countries across four continents [Research Support, Non-U.S. Gov’t]. J Comp Eff Res. 2015 Sep;4(5):485–504. PubMed PMID: 26490020; eng.
3. Weinstein M, Zeckhauser R., Critical ratios and efficient allocation. J Public Econ. 1973;2:147–157.
4. Kirkdale R, Krell J, Brown CO, et al. The cost of a QALY. QJM: Month J Assoc Phys. 2010 Sep;103(9):715–720. PubMed PMID: 20519275; eng.
5. Paris V, Belloni A., Value in pharmaceutical pricing. France: OECD; 2013.
6. Rascati KL. Essentials of pharmacoeconomics. Philadelphia: Lippincott Williams & Wilkins; 2009.
7. Drummond MF, Sculpher MJ, Claxton K, et al. Methods for the economic evaluation of health care programmes. Vol. 4. United Kingdom: Oxford University Press; 2015.
8. Kelly RJ, Smith TJ. Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer care. Lancet Oncol. 2014;15(3):e112–8.
9. Kantarjian H, Steensma D, Rius Sanjuan J, et al. High cancer drug prices in the United States: reasons and proposed solutions. J Oncol Pract. 2014 Jul;10(4):e208–11. PubMed PMID: 24803662; eng.
10. Howard DH, Bach PB, Berndt ER, et al. Pricing in the Market for Anticancer Drugs. J Econ Perspect: J Am Econ Assoc. 2015;29(1):139–162. PubMed PMID: 28441702; eng.
11. Godman B, Oortwijn W, Waure C, et al. Links between pharmaceutical R&D models and access to affordable medicines. Brussels: European Parliament; 2016.
12. Godman B, Wild C, Haycox A. Patent expiry and costs for anti-cancer medicines for clinical use. Gener Biosimil Initiative J. 2017;1–3. Available from: https://strathprints.strath.ac.uk/60241/.
13. Haji Ali Afzali H, Karnon J, Sculpher M. Should the Lambda (lambda) remain silent? Pharmacoeconomics. 2016 Apr;34(4):323–329. PubMed PMID: 26660350; eng. DOI:10.1007/s40273-015-0359-7.
14. Newall AT, Jit M, Hutubessy R. Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines [Research Support, Non-U.S. Gov’t]. Pharmacoeconomics. 2014 Jun;32(6):525–531. PubMed PMID: 24791735; eng. DOI:10.1007/s40273-014-0162-x.
15. Bertram MY, Lauer JA, De Joncheere K, et al. Cost-effectiveness thresholds: pros and cons. Bull World Health Organ. 2016 Dec 01;94(12):925–930. PubMed PMID: 27994285; eng.
16. Marseille E, Larson B, Kazi DS, et al. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ. 2015 Feb 01;93(2):118–124. PubMed PMID: 25883405; PubMed Central PMCID: PMC4339959. eng.
17. Claxton K, Martin S, Soares M, et al. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technol Assess. 2015 Feb;19(14):1–503, v-vi. PubMed PMID: 25692211; PubMed Central PMCID: PMC4781395. eng. DOI:10.3310/hta19140.
18. Eichler H-G, Kong SX, Gerth WC, et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health. 2004;7(5):518–528.
19. Brasil. Decreto no. 7.646 de 21 de dezembro de 2011. Brasília: Imprensa Nacional; 2011.
20. Brasil. Lei no. 12.401 de 28 de abril de 2011. Brasília: Imprensa Nacional; 2011.
21. Pinto M, Santos M, Trajman A. Limiar de custo-efetividade: uma necessidade para o Brasil? J Bras Econ Saúde. 2016;8(1):58–60.
22. Remme M, Martinez-Alvarez M, Vassall A. Cost-effectiveness thresholds in global health: taking a multisectoral perspective. Value Health. 2016. DOI:10.1016/j.jval.2016.11.009
23. Svensson M, Nilsson FO, Arnberg K. Reimbursement decisions for pharmaceuticals in Sweden: the impact of disease severity and cost effectiveness [Research Support, Non-U.S. Gov’t]. Pharmacoeconomics. 2015 Nov;33(11):1229–1236. PubMed PMID: 26093889; eng. DOI:10.1007/s40273-015-0307-6.
24. Cleemput I, Neyt M, Thiry N, et al. Using threshold values for cost per quality-adjusted life-year gained in healthcare decisions [Research Support, Non-U.S. Gov’t Review]. Int J Technol Assess Health Care. 2011 Jan;27(1):71–76. PubMed PMID: 21262069; eng.
25. Grosse SD. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res. 2008 Apr;8(2):165–178. PubMed PMID: 20528406; eng. DOI:10.1586/14737167.8.2.165.
26. McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold: what it is and what that means. Pharmacoeconomics. 2008;26(9):733–744. PubMed PMID: 18767894; eng.
27. Claxton K, Briggs A, Buxton MJ, et al. Value based pricing for NHS drugs: an opportunity not to be missed? BMJ (Clinical Research Ed). 2008 Feb 02;336(7638):251–254. PubMed PMID: 18244997; PubMed Central PMCID: PMCPMC2223028.
28. Cairns J. Using cost-effectiveness evidence to inform decisions as to which health services to provide. Health Syst Reform. 2016;2(1):32–38.
29. Culyer AJ. Cost-effectiveness thresholds in health care: a bookshelf guide to their meaning and use. Health Econ Policy Law. 2016 Oct;11(4):415–432. PubMed PMID: 26906561; eng. DOI:10.1017/s1744133116000049.
30. Revil P, Walker S, Madan J, et al. Using cost-effectiveness thresholds to determine value for money in low-and middle-income country healthcare systems: are current international norms fit for purpose? York: Centre for Health Economics; 2014.
31. The Economist Intelligence Unit Healthcare. Value-based healthcare: the implications for pharma strategy. Econ. 2014;1-35. Available from: http://www.eiu.com/public/thankyou_download.aspx?activity=download&campaignid=PharmaStrat0314.
32. Matusewicz W, Godman B, Pedersen HB, et al. Improving the managed introduction of new medicines: sharing experiences to aid authorities across Europe [Congresses]. Expert Rev Pharmacoecon Outcomes Res. 2015;15(5):755–758. PubMed PMID: 26368060; eng. DOI:10.1586/14737167.2015.1085803.
33. Harris AH, Hill SR, Chin G, et al. The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994-2004 [Research Support, Non-U.S. Gov’t]. Med Dec Making: Int J Soc Med Dec Making. 2008 Sep-Oct;28(5):713–722. PubMed PMID: 18378939; eng.
34. Llano-Señarís J, Campillo-Artero C. Health technology assessment and health policy today: a multifaceted view of their unstable crossroads. Switzerland: Springer International Publishing; 2015.
35. Woods B, Revill P, Sculpher M, et al. Country-level cost-effectiveness thresholds: initial estimates and the need for further research. Value Health. 2016;19(8):929–935. DOI:10.1016/j.jval.2016.02.017.
36. Brasil. CONITEC participa de audiência no Senado sobre limiar de custo-efetividade Brasília. CONITEC. 2017 [cited 2017 Aug 25]. Available from: http://conitec.gov.br/ultimas-noticias-3/16770-conitec-participa-de-audiencia-no-senado-sobre-limiar-de-custo-efetividade
37. Paulden M, O’Mahony J, McCabe C. Determinants of change in the cost-effectiveness threshold. Med Dec Making: Int J Soc Med Dec Making. 2016 Aug 23. PubMed PMID: 27553208; eng. DOI:10.1177/0272989X16662242.
38. Vallejo-Torres L, García-Lorenzo B, Serrano-Aguilar P. Estimating a cost-effectiveness threshold for the Spanish NHS. Health Econ. 2017. DOI:10.1002/hec.3633
39. Institute for Quality and Efficiency in Health Care. General methods for the assessment of the relation of benefits to costs. Cologne: Institute for Quality and Efficiency in Health Care; 2009.
40. Caro JJ, Nord E, Siebert U, et al. The efficiency frontier approach to economic evaluation of health-care interventions [Research Support, Non-U.S. Gov’t]. Health Econ. 2010 Oct;19(10):1117–1127. PubMed PMID: 20575151; eng.
41. Vallejo-Torres L, Garcia-Lorenzo B, Castilla I, et al. On the estimation of the cost-effectiveness threshold: why, what, how? Value Health: J Int Soc Pharmacoeconomics Outcomes Res. 2016 Jul-Aug;19(5):558–566. PubMed PMID: 27565273; eng.
42. Godoi IP, Santos AS, Reis EA, et al. Consumer willingness to pay for dengue vaccine (CYD-TDV, Dengvaxia(R)) in Brazil; Implications for future pricing considerations. Front Pharmacol. 2017;8:41. PubMed PMID: 28210223; PubMed Central PMCID: PMC5288336. eng. DOI:10.3389/fphar.2017.00041.
43. Shiroiwa T, Sung YK, Fukuda T, et al. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? [Research Support, Non-U.S. Gov’t]. Health Econ. 2010 Apr;19(4):422–437. PubMed PMID: 19382128; eng.
44. Haab TC, McConnell KE. Valuing environmental and natural resources: the econometrics of non-market valuation. Cheltenham (UK): E. Elgar Pub; 2002. ((New horizons in environmental economics)).
45. Arrow K, Solow R, Portney PR, et al. Report of the NOAA panel on contingent valuation. Federal register 58: National Oceanic and Atmospheric Administration; 1993.
46. Foreit KGF, Foreit JR. Willingness to pay surveys for setting prices for reproductive health products and services: a user´s manual. New York: Population Council; 2004. Available from: https://www.thehealthcompass.org/sites/default/files/strengthening_tools/WTP_Manual.pdf.
47. Lee JS, Mogasale V, Lim JK, et al. A multi-country study of the household willingness-to-pay for dengue vaccines: household surveys in Vietnam, Thailand, and Colombia. PLoS Negl Trop Dis. 2015;9(6):e0003810. PubMed PMID: 26030922; PubMed Central PMCID: PMCPMC4452082. DOI:10.1371/journal.pntd.0003810.
48. Kahneman D, Knetsch JL, Thaler RH. Experimental tests of the endowment effect and the coase theorem. J Political Econ. 1990;98(6):1325–1348.
49. Kahneman D, Knetsch JL, Thaler RH. The endowment effect, loss aversion, and status quo bias. J Econ Perspect. 1991;5(1):193–206.
50. Culyer A, McCabe C, Briggs A, et al. Searching for a threshold, not setting one: the role of the national institute for health and clinical excellence. J Health Serv Res Policy. 2007 Jan;12(1):56–58. PubMed PMID: 17244400.
51. Eckermann S, Pekarsky B. Can the real opportunity cost stand up: displaced services, the straw man outside the room. Pharmacoeconomics. 2014 Apr;32(4):319–325. PubMed PMID: 24515251; eng. DOI:10.1007/s40273-014-0140-3.
52. Ermisch M, Bucsics A, Vella Bonanno P, et al. Payers’ views of the changes arising through the possible adoption of adaptive pathways. Front Pharmacol. 2016;7:305. PubMed PMID: 27733828; PubMed Central PMCID: PMC5039228. eng. DOI:10.3389/fphar.2016.00305.
53. Fleury S, Ouverney AM. Política de Saúde: uma política social. Políticas e Sistema de Saúde no Brasil. Rio de Janeiro: Fiocruz; 2008.
54. Thavorncharoensap M, Teerawattananon Y, Natanant S, et al. Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter? ClinicoEconomics Outcomes Res: CEOR. 2013;5:29–36. PubMed PMID: 23345984; PubMed Central PMCID: PMC3548562. eng. DOI:10.2147/CEOR.S38062.
55. Ottersen T, Førde R, Kakad M, et al. A new proposal for priority setting in Norway: open and fair. Health Policy. 2016;120(3):246–251.
56. Blumstein JF. The Oregon experiment: the role of cost-benefit analysis in the allocation of Medicaid funds. Soc Sci Med. 1997 Aug;45(4):545–554. PubMed PMID: 9226780; eng.
57. Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness–the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014 Aug 28;371(9):796–797. PubMed PMID: 25162885; eng. DOI:10.1056/NEJMp1405158.
58. Neumann PJ, Cohen JT. ICER’s revised value assessment framework for 2017-2019: A critique [letter]. Pharmacoeconomics. 2017 Aug 08;35:977–980. PubMed PMID: 28791663; eng. DOI:10.1007/s40273-017-0560-y.
59. Ubel PA, Hirth RA, Chernew ME, et al. What is the price of life and why doesn’t it increase at the rate of inflation? [Comment Review]. Arch Intern Med. 2003 Jul 28;163(14):1637–1641. PubMed PMID: 12885677; eng.
60. Haycox A. Why cancer? [Editorial]. Pharmacoeconomics. 2016 Jul;34(7):625–627. 10.1007/s40273-016-0413-0. PubMed PMID: 27194312; PubMed Central PMCID: PMC4901109. eng.
61. Simoens S, Picavet E, Dooms M, et al. Cost-effectiveness assessment of orphan drugs: a scientific and political conundrum [EditorialResearch Support, Non-U.S. Gov’t]. Appl Health Econ Health Policy. 2013 Feb;11(1):1–3. PubMed PMID: 23329382; eng.
62. Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis. 2011 Jun 17;6:42. PubMed PMID: 21682893; PubMed Central PMCID: PMC3132155. eng. DOI:10.1186/1750-1172-6-42.
63. Barrett A, Roques T, Small M, et al. How much will Herceptin really cost? [Review]. BMJ (Clinical Research Ed). 2006 Nov 25;333(7578):1118–1120. PubMed PMID: 17124225; PubMed Central PMCID: PMC1661755. eng.
64. Gafni A, Birch S. Inclusion of drugs in provincial drug benefit programs: should “reasonable decisions” lead to uncontrolled growth in expenditures? [Comment]. CMAJ: Can Med Assoc Jl = Journal De l’Association Medicale Canadienne. 2003 Apr 01;168(7):849–851. PubMed PMID: 12668543; PubMed Central PMCID: PMC151991. eng.
65. Mauskopf J, Rutten F, Schonfeld W. Cost-effectiveness league tables: valuable guidance for decision makers? Pharmacoeconomics. 2003;21(14):991–1000. PubMed PMID: 13129413; eng.
66. Gerard K, Mooney G. QALY league tables: handle with care [Research Support, Non-U.S. Gov’t Review]. Health Econ. 1993 Apr;2(1):59–64. PubMed PMID: 8269048; eng.
67. Guide to the methods of technology appraisal. 2013.
68. Drummond M, Torrance G, Mason J. Cost-effectiveness league tables: more harm than good? [Comparative Study]. Soc Sci Med. 1993 Jul;37(1):33–40. PubMed PMID: 8332922; eng.
69. Paulden M, McCabe C, Karnon J. Achieving allocative efficiency in healthcare: nice in theory, not so NICE in Practice? [CommentEditorial]. Pharmacoeconomics. 2014 Apr;32(4):315–318. PubMed PMID: 24599785; eng. DOI:10.1007/s40273-014-0146-x.
70. Schwartz B. The paradox of choice: why more is less. 1st ed. New York: Ecco; 2004.
71. Franken M, Koopmanschap M, Steenhoek A. Health economic evaluations in reimbursement decision making in the Netherlands: time to take it seriously? Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen. 2014;108(7):383–389.
72. World Health Organization. Macroeconomics and health: investing in health for economic development. Geneva: World Health Organization; 2001. Available from: http://www1.worldbank.org/publicsector/pe/PEAMMarch2005/CMHReport.pdf.
73. Bertram M. Response of Melanie Bertram to professor Anthony Culyer’s open letter to Dr. Tedros. World Health Organization. Available from: https://www.cgdev.org/sites/default/files/WHO-response-melanie-bertram.pdf.
74. Brasil. Diretrizes Metodológicas: diretriz de avaliação econômica. 2nd ed. Brasília: Ministério da Saúde; 2014.
75. Brasil. Portaria N°. 2.009, de 13 de setembro de 2012. Brasília: Ministério da Saúde; 2012.
76. Yuba TY, Novaes HM, De Soárez PC. PHP50 - use of incremental cost-effectiveness ratio (Icer) in recommending technologies incorporation in the Brazilian public health system (Sus), 2012-2015. Value Health. 2015;18(7):A523.
77. Ribeiro AAR. Perfil de recomendações da Conitec quanto à incorporação de novas tecnologias no SUS. Belo Horizonte: Universidade Federal de Minas Gerais; 2017.
78. Custódio PAG. Estudo descritivo dos medicamentos avaliados para incorporação no período de 2012 a 2016 pela Conitec. Belo Horizonte: Universidade Federal de Minas Gerais; 2017.
79. Ribeiro RA, Neyeloff JL, Marcolino MA, et al. Cost-effectiveness threshold in brazil through a league-table approach: systematic review. 6th ISPOR Latin America; Sao Paulo; 2017.
80. Lemmer T, Saad R, Piedade A, et al. Conitec Reimbursement decisions: is there a cost-utility decision threshold? ISPOR 6th Latin America Conference; São Paulo: ISPOR; 2017.
81. Pichon-Riviere A, Augustovski F, Marti SG, The efficiency path to universal health coverage: derivation of cost-effectiveness thresholds based on health expenditures and life expectancy. Updated country-level estimates for 194 countries. 6th ISPOR Latin America; Sao Paulo: ISPOR; 2017.
82. Chambers JD, Neumann PJ, Buxton MJ. Does Medicare have an implicit cost-effectiveness threshold? Med Dec Making: Int J Soc Med Dec Making. 2010 Jul-Aug;30(4):E14–27. PubMed PMID: 20551473; eng. DOI:10.1177/0272989x10371134.
83. Braithwaite RS, Meltzer DO, King JT, Jr., et al. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care. 2008 Apr;46(4):349–356. PubMed PMID: 18362813; eng.
84. Paulden M, O’Mahony JF, Culyer AJ, et al. Some inconsistencies in NICE’s consideration of social values. Pharmacoeconomics. 2014 Nov;32(11):1043–1053. PubMed PMID: 25145802; eng.
85. Airoldi M, Morton A, Smith JA, et al. STAR–people-powered prioritization: a 21st-century solution to allocation headaches [Research Support, Non-U.S. Gov’t]. Med Dec Making: Int J Soc Med Dec Making. 2014 Nov;34(8):965–975. PubMed PMID: 25118084; eng.
86. Griffiths EA, Vadlamudi NK. PHP278 - Cadth’s $50,000 Cost-effectiveness threshold: fact or fiction? Value Health. 2016;19(7):A488–A489.
87. Nimdet K, Ngorsuraches S. Willingness to pay per quality-adjusted life year for life-saving treatments in Thailand. BMJ Open. 2015 Oct 05;5(10):e008123. PubMed PMID: 26438135; PubMed Central PMCID: PMC4606417. eng. DOI:10.1136/bmjopen-2015-008123.
88. Whitty JA, Littlejohns P. Social values and health priority setting in Australia: an analysis applied to the context of health technology assessment. Health Policy. 2015;119(2):127–136.
89. Paris V, Belloni A. Value in pharmaceutical pricing: country profile - Australia. Paris: OECD; 2014.
90. Jakubiak-Lasocka J, Jakubczyk M. Cost-effectiveness versus cost-utility analyses: what are the motives behind using each and how do their results differ?—A Polish example. Value Health Reg Issues. 2014;4c:66–74.
91. Grzywacz K, Pelczarska A, Witkowski MA, et al. The cost-effectiveness threshold for orphan designations in poland based on reimbursement decisions. Value Health: J Int Soc Pharmacoeconomics Outcomes Res. 2014 Nov;17(7):A450. PubMed PMID: 27201232; eng.
92. Niewada M, Polkowska M, Jakubczyk M, et al. What influences recommendations issued by the agency for health technology assessment in Poland? A glimpse into decision Makers’ preferences. Value Health Reg Issues. 2013;2(2):267–272.
93. Godman B, Paterson K, Malmstrom RE, et al. Improving the managed entry of new medicines: sharing experiences across Europe [Congresses]. Expert Rev Pharmacoecon Outcomes Res. 2012 Aug;12(4):439–441. PubMed PMID: 22971029; eng.
94. Klingler C, Shah SM, Barron AJ, et al. Regulatory space and the contextual mediation of common functional pressures: analyzing the factors that led to the German efficiency frontier approach [Research Support, Non-U.S. Gov’t, Review]. Health Policy. 2013 Mar;109(3):270–280. PubMed PMID: 23380191; eng.
95. Stollenwerk B, Lhachimi SK, Briggs A, et al. Communicating the parameter uncertainty in the IQWiG efficiency frontier to decision-makers. Health Econ. 2014 Apr;24(4):481–490. PubMed PMID: 24590819; PubMed Central PMCID: PMC4489337. eng.
96. Sculpher M, Claxton K. Sins of omission and obfuscation: IQWIG’s guidelines on economic evaluation methods [Comment]. Health Econ. 2010 Oct;19(10):1132–1136. PubMed PMID: 20662107; eng. DOI:10.1002/hec.1645.
97. O’Mahony JF, Coughlan D. The Irish cost-effectiveness threshold: does it support rational rationing or might it lead to unintended harm to Ireland’s health system? Pharmacoeconomics. 2016 Jan;34(1):5–11. PubMed PMID: 26497002; eng. DOI:10.1007/s40273-015-0336-1.
98. O’Mahony J, Coughlan D. The Irish cost-effectiveness threshold: does it support rational rationing or might it lead to systematic damage of Ireland’s health system? Value Health: J Int Soc Pharmacoeconomics Outcomes Res. 2014 Nov;17(7):A451. PubMed PMID: 27201239; eng. DOI:10.1016/j.jval.2014.08.1220.
99. Kamae I, Sugimoto T. PHP41 - experience seeking appropriate standards of cost-effectiveness ratio: updates and challenges in Japanese setting. Value Health. 2016;19(7):A821.
100. Metcalfe S, Rodgers A, Werner R, et al. PHARMAC has no cost-effectiveness threshold. N Z Med J. 2012 Feb 24;125(1350):99–101. PubMed PMID: 22382263; eng
101. Pharmaceutical Management Agency. Cost-utility analysis (CUA) explained. New Zealand: Pharmaceutical Management Agency; 2012.
102. Godman B, Malmstrom RE, Diogene E, et al. Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? [Review]. Expert Rev Clin Pharmacol. 2015 Jan;8(1):77–94. PubMed PMID: 25487078; eng. DOI:10.1586/17512433.2015.990380.
103. Van Kampen RJW, Ramaekers BLT, Lobbezoo DJA, et al. Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium. Eur J Cancer. 2017 Jul;79:238–246. PubMed PMID: 28245951.
104. Helsper CW, Janssen MP, GAv E, et al. Effectiveness and cost-effectiveness of nationwide campaigns for awareness and case finding of hepatitis C targeted at people who inject drugs and the general population in the Netherlands. Int J Drug Policy. 2017;47:117–125.
105. De Jong LA, Dvortsin E, Janssen KJ, et al. Cost-effectiveness analysis for apixaban in the acute treatment and prevention of venous thromboembolism in the Netherlands. Clin Ther. 2017 Feb;39(2):288–302 e4. PubMed PMID: 28139289.
106. Van Der Pol S, Degener F, Postma MJ, et al. An economic evaluation of Sacubitril/Valsartan for heart failure patients in the Netherlands. Value Health: J Int Soc Pharmacoeconomics Outcomes Res. 2017 Mar;20(3):388–396. PubMed PMID: 28292483.
107. Jiménez E, Torkilseng EB, Klemp M. Cost-effectiveness of HPV-vaccination of boys aged 12 in a Norwegian setting. Oslo: Norwegian Knowledge Centre for the Health Service; 2015.
108. Burger EA, Sy S, Nygard M, et al. Prevention of HPV-related cancers in Norway: cost-effectiveness of expanding the HPV vaccination program to include pre-adolescent boys. PloS One. 2014;9(3):e89974. PubMed PMID: 24651645; PubMed Central PMCID: PMC3961226. eng. DOI:10.1371/journal.pone.0089974.
109. Samdal K, Hagen G, Flem E, et al. Kostnadseffektivitet av å inkludere vaksinasjon mot rotavirus i det norske barnevaksinasjonsprogrammet. Oslo: Nasjonalt kunnskapssenter for helsetjenesten; 2009.
110. Amorim FF, Júnior PNF, Faria ER, et al. Avaliação de Tecnologias em Saúde: contexto Histórico e Perspectivas. Com Ciências Saúde. 2010;21(4):343–348.
111. Pereira VC, Salomon FCR, Souza A. Critérios para decisões sobre incorporação de tecnologias em saúde no Brasil e no mundo. Revista Eletrônica Gestão & Saúde. 2015;6:3066–3093.
112. Newhouse JP. Medical care costs: how much welfare loss? [Review]. J Econ Perspect: J Am Econ Assoc. 1992 Summer;6(3):3–21. PubMed PMID: 10128078; eng.
113. Teerawattananon Y, Tritasavit N, Suchonwanich N, et al. The use of economic evaluation for guiding the pharmaceutical reimbursement list in Thailand. Z Evid Fortbild Qual Gesundh Wesen. 2014;108:397—404.
114. Nord E, Richardson J, Street A, et al. Maximizing health benefits vs egalitarianism: an Australian survey of health issues. Soc Sci Med. 1995 Nov;41(10):1429–1437. PubMed PMID: 8560311; eng.
115. Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 2013 May 30;121(22):4439–4442. PubMed PMID: 23620577; PubMed Central PMCID: PMC4190613. eng. DOI:10.1182/blood-2013-03-490003
116. Ghinea N, Kerridge I, Lipworth W. If we don’t talk about value, cancer drugs will become terminal for health systems. Boston: The Conversation; 2015.
117. Tefferi A, Kantarjian H, Rajkumar SV, et al. In support of a patient-driven initiative and petition to lower the high price of cancer drugs. Mayo Clin Proc. 2015 Aug;90(8):996–1000. PubMed PMID: 26211600; PubMed Central PMCID: PMCPMC5365030.
118. Hill A, Gotham D, Fortunak J, et al. Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment. BMJ Open. 2016 Jan 27;6(1):e009586. PubMed PMID: 26817636; PubMed Central PMCID: PMCPMC4735306.
119. Prescrire. New drugs, new indications in 2015: little progress, and threats to access to quality healthcare for all. Rev Prescrire. 2016;36(388):133–137.
120. De Pouvourville G. Risk-sharing agreements for innovative drugs: a new solution to old problems? [Editorial]. Euro J Health Econ: HEPAC: Health Econ Prev Care. 2006 Sep;7(3):155–157. PubMed PMID: 16912890; eng. DOI:10.1007/s10198-006-0386-6.
121. Ferrario A, Araja D, Bochenek T, et al. The implementation of managed entry agreements in central and Eastern Europe: findings and implications. Pharmacoeconomics. 2017 Dec;35(12):1271–1285. 10.1007/s40273-017-0559-4. PubMed PMID: 28836222; PubMed Central PMCID: PMCPMC5684278.
122. Kaló Z, Gheorghe A, Huic M, et al. HTA implementation roadmap in central and Eastern European countries. Health Econ. 2016;25. DOI:10.1002/hec.3298.
123. Brennan T, Shrank W. New expensive treatments for hepatitis C infection. JAMA. 2014 Aug 13;312(6):593–594. PubMed PMID: 25038617. DOI:10.1001/jama.2014.8897.